JP2018513204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513204A5 JP2018513204A5 JP2017555718A JP2017555718A JP2018513204A5 JP 2018513204 A5 JP2018513204 A5 JP 2018513204A5 JP 2017555718 A JP2017555718 A JP 2017555718A JP 2017555718 A JP2017555718 A JP 2017555718A JP 2018513204 A5 JP2018513204 A5 JP 2018513204A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- creatine hydrochloride
- grams
- amount
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 31
- DGOAYHVIVJYHKU-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrochloride Chemical compound Cl.NC(=N)N(C)CC(O)=O DGOAYHVIVJYHKU-UHFFFAOYSA-N 0.000 claims 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 235000015872 dietary supplement Nutrition 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 102100027840 Acyl-CoA wax alcohol acyltransferase 1 Human genes 0.000 claims 1
- 101000698136 Homo sapiens Acyl-CoA wax alcohol acyltransferase 1 Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007963 capsule composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 241000411851 herbal medicine Species 0.000 claims 1
- 230000001632 homeopathic effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078285A JP2021120388A (ja) | 2015-04-20 | 2021-05-06 | 神経保護および神経変性の治療のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150113P | 2015-04-20 | 2015-04-20 | |
| US62/150,113 | 2015-04-20 | ||
| PCT/US2016/028357 WO2016172148A1 (en) | 2015-04-20 | 2016-04-20 | Compositions and methods for neuroprotection and treatment of neurodegeneration |
| US15/133,501 | 2016-04-20 | ||
| US15/133,501 US10245245B2 (en) | 2015-04-20 | 2016-04-20 | Compositions and methods for neuroprotection and treatment of neurodegeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078285A Division JP2021120388A (ja) | 2015-04-20 | 2021-05-06 | 神経保護および神経変性の治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513204A JP2018513204A (ja) | 2018-05-24 |
| JP2018513204A5 true JP2018513204A5 (enExample) | 2019-03-14 |
| JP6882191B2 JP6882191B2 (ja) | 2021-06-02 |
Family
ID=57128180
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555718A Active JP6882191B2 (ja) | 2015-04-20 | 2016-04-20 | 神経保護および神経変性の治療のための組成物および方法 |
| JP2021078285A Pending JP2021120388A (ja) | 2015-04-20 | 2021-05-06 | 神経保護および神経変性の治療のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078285A Pending JP2021120388A (ja) | 2015-04-20 | 2021-05-06 | 神経保護および神経変性の治療のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10245245B2 (enExample) |
| EP (1) | EP3285755B1 (enExample) |
| JP (2) | JP6882191B2 (enExample) |
| CA (1) | CA2983151C (enExample) |
| ES (1) | ES2903136T3 (enExample) |
| PL (1) | PL3285755T3 (enExample) |
| WO (1) | WO2016172148A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2903136T3 (es) | 2015-04-20 | 2022-03-31 | Vireo Systems Inc | Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington |
| US11154499B2 (en) | 2018-03-27 | 2021-10-26 | Thermolife International, Llc | Creatine and/or creatinine compositions and related methods |
| MX2020010159A (es) * | 2018-03-27 | 2021-02-26 | Thermolife Int Llc | Composiciones de creatina y/o creatinina y metodos relacionados. |
| US11260096B2 (en) | 2019-06-28 | 2022-03-01 | Thermolife International, Llc | Compositions for creatine supplementation in creatine non-responders |
| WO2022109465A1 (en) | 2020-11-23 | 2022-05-27 | Vireo Systems, Inc. | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1719510A1 (en) | 1994-11-08 | 2006-11-08 | Avicenda Group, Inc. | Use of creatine or creatine analogs for the tratment of diseases of the nervous system |
| EP1363509B1 (en) * | 2001-03-02 | 2006-10-11 | The Howard Foundation | Compositions containing creatine and creatinine |
| US8354450B2 (en) | 2003-05-15 | 2013-01-15 | Vireo Systems, Inc. | Creatine oral supplementation using creatine hydrochloride salt |
| US7608641B2 (en) | 2003-05-15 | 2009-10-27 | Board Of Regents Of The University Of Nebraska | Creatine oral supplementation using creatine hydrochloride salt |
| CA2610856A1 (en) | 2005-06-13 | 2006-12-28 | Stratagene California | System and method for fluorescence excitation and detection having distinct optical paths |
| AU2007249847A1 (en) | 2006-05-11 | 2007-11-22 | Avicena Group, Inc. | Methods of treating a neurological disorder with creatine monohydrate |
| US7683043B2 (en) | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| JP5433571B2 (ja) * | 2007-06-05 | 2014-03-05 | フェノーリックス、エルエルシー | 経口クレアチンの骨格における取り込みを増強するための腸溶性コーティングを施した可溶性クレアチン及びポリエチレングリコールの組成物 |
| US8445466B2 (en) * | 2010-04-08 | 2013-05-21 | John H. Owoc | Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof |
| WO2015095199A1 (en) * | 2013-12-16 | 2015-06-25 | Vireo Systems, Inc. | Method and composition for treating osteoarthritis |
| ES2903136T3 (es) * | 2015-04-20 | 2022-03-31 | Vireo Systems Inc | Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington |
-
2016
- 2016-04-20 ES ES16783719T patent/ES2903136T3/es active Active
- 2016-04-20 US US15/133,501 patent/US10245245B2/en active Active
- 2016-04-20 JP JP2017555718A patent/JP6882191B2/ja active Active
- 2016-04-20 PL PL16783719T patent/PL3285755T3/pl unknown
- 2016-04-20 EP EP16783719.4A patent/EP3285755B1/en active Active
- 2016-04-20 CA CA2983151A patent/CA2983151C/en active Active
- 2016-04-20 WO PCT/US2016/028357 patent/WO2016172148A1/en not_active Ceased
-
2019
- 2019-04-01 US US16/371,779 patent/US10583105B2/en active Active
-
2020
- 2020-03-09 US US16/812,835 patent/US11160776B2/en active Active
-
2021
- 2021-05-06 JP JP2021078285A patent/JP2021120388A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513204A5 (enExample) | ||
| BRPI0610180A2 (pt) | métodos para prevenir, para tratar, e para tratar ou controlar uma condição associada à inflamação | |
| RU2015147874A (ru) | Композиция, содержащая комбинацию экстракта бузины и штамма lactobacillus rhamnosus | |
| JP2016516058A5 (enExample) | ||
| CN107708688A (zh) | 使用天然化合物和/或饮食治疗炎症的方法 | |
| HRP20240115T1 (hr) | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom | |
| CN103432184B (zh) | 牛蒡子提取物在制药或食品中的应用 | |
| CN105832794A (zh) | 平卧菊三七在制备防治高尿酸血症药物、保健食品或功能食品中的应用 | |
| CN101822726B (zh) | 一种具有保肝护肝作用的药品或者保健食品 | |
| CN101879182A (zh) | 一种用于抗辐射的复合多糖 | |
| CN105663099A (zh) | 芦荟大黄素在制备降血脂以及降肝脂药物中的用途 | |
| CN102657686B (zh) | 沙棘籽油在制备预防和/或治疗抑郁症药物中的应用 | |
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma | |
| CN109172663B (zh) | 一种治疗焦虑抑郁的药物组合物及其应用 | |
| RU2014146562A (ru) | Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий | |
| JP2023075284A (ja) | 経口組成物 | |
| WO2012141615A3 (ru) | Лекарственное средство | |
| JP2012046484A5 (enExample) | ||
| JP2017515858A5 (enExample) | ||
| JP2007230989A (ja) | 持久力増強・抗疲労剤 | |
| CN106560178A (zh) | 一种含厚朴酚及和厚朴酚与非甾体抗炎药组合物及其应用 | |
| CN104815020A (zh) | 一种用于治疗抑郁症的植物油组合物 | |
| CN115397416A (zh) | 包含仑伐替尼的分子水平的药物组合物及其制备方法和应用 | |
| CN101385726A (zh) | α-硫辛酸在制备改善老年记忆功能药物或食品中的用途 | |
| CN108686119A (zh) | 一种治疗痛风的药物组合物及其应用 |